Jennifer Michaelson, Chief Scientific Officer at Cullinan Therapeutics, Inc. (NASDAQ:CGEM), recently sold 4,693 shares of the company’s common stock. The transaction took place on December 18, 2024, at a price of $11.41 per share, amounting to a total value of $53,547. The sale comes as CGEM, currently valued at $679 million, trades near oversold territory according to technical indicators. InvestingPro analysis shows the stock has declined about 37% over the past six months, though it maintains a strong balance sheet with more cash than debt. Following the sale, Michaelson retains ownership of 99,760 shares. The sale was conducted to cover personal income tax obligations upon the vesting of restricted stock units, as noted in the filing. While the company faces near-term profitability challenges, analysts maintain an optimistic outlook, with four analysts recently revising earnings estimates upward. Track insider transactions and access detailed company analysis with InvestingPro, which offers additional valuable insights about CGEM’s financial health and market position.
In other recent news, Cullinan Oncology has made significant strides in its clinical trials and drug development. The biopharmaceutical company reported a lower-than-expected Q1 loss of $0.86 per share, outperforming the projected loss of $0.94. Clear Street initiated coverage of the firm with a Buy rating and a target price of $30.00, while BTIG and UBS also maintained Buy ratings with similar price targets. Analysts from these firms highlighted the potential of Cullinan’s immunology and inflammation drug, CLN-978, which is being evaluated for its potential to address the needs of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
The U.S. Food and Drug Administration has also approved Cullinan’s Investigational New Drug (IND) application for CLN-978. With the clearance, the company can proceed with its global Phase 1 clinical trial, targeting moderate to severe SLE patients. This development follows promising preclinical data presented at the annual American College of Rheumatology meeting.
In terms of leadership changes, Cullinan Oncology welcomed Mary Kay Fenton as its new Chief Financial Officer and elected Anne-Marie Martin, Ph.D., and David Meek as Class I directors to the Board. These recent developments are shaping the trajectory of Cullinan Oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.